Loss of expression of the p16 tumor suppressor gene is more frequent in advanced ovarian cancers lacking p53 mutations

Gynecologic Oncology

Volumn 83, Issue 3, 2001, Pages 491-500

  Havrilesky, Laura J ^a   Alvarez, Angeles A ^a   Whitaker, Regina S ^a   Marks, Jeffrey R ^b   Berchuck, Andrew ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; CYCLIN E; KI 67 ANTIGEN; PROTEIN P14; PROTEIN P16; PROTEIN P27; PROTEIN P53; RETINOBLASTOMA PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CARCINOGENESIS; CELL CYCLE G1 PHASE; CONTROLLED STUDY; GENE DELETION; GENE INACTIVATION; GENE MUTATION; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; OVARY CANCER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEQUENCE ANALYSIS; TUMOR SUPPRESSOR GENE;

EID: 0035209680     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.2001.6464     Document Type: Article

References (49)

1. The p53 proto-oncogene can act as a suppressor of transformation
2. The p53 tumour suppressor gene
3. A retroviral wild-type p53 expression vector penetrates human lung cancer spheroids and inhibits growth by inducing apoptosis
4. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene
5. The p53 tumor suppressor gene frequently is altered in gynecologic cancers
6. Relationship between p53 mutation, p53 overexpression and survival in advanced ovarian cancers treated on Gynecologic Oncology Group Protocols 114 and 132
7. Presence and location of TP53 mutation determines pattern of CDKN2A/ARF pathway inactivation in bladder cancer
8. Different combinations of genetic/epigenefic alterations inactivate the p53 and pRb pathways in invasive human bladder cancers
9. Reactivity of a monoclonal antibody with human ovarian carcinoma
10. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4
11. A cell cycle regulator potentially involved in genesis of many tumor types
12. MTSI/p16/CDKN2 lesions in primary glioblastoma multiforme
13. Higher frequency of alterations in the p16/CDKN2 gene in squamous cell carcinoma cell lines than in primary tumors of the head and neck
14. p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma
15. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma
16. 5′ CpG island methyladon is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers
17. Methylation of the 5′ CpG island of the p16/ CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing
18. Elevated p16 at senescence and loss of p16 at immortalization in human papillomavirus 16 E6, but not E7, transformed human uroepithelial cells
19. INK4A upon immortalization
20. Alterations of the p16INK4A gene in human ovarian cancers
21. Inactivation of p16/CDKN2 and p15/MTS2 genes in different histological types and clinical stages of primary ovarian tumors
22. Detailed deletion mapping of chromosome 9p and p16 gene alterations in human borderline and invaslve epithelial ovarian tumors
23. Analysis of the p16 tumor suppressor gene in early-stage prostate cancer
24. Absence of deletions but frequent loss of expression of p16INK4 in human ovarian tumours
25. Alteration of p16 and p15 genes in common epithelial ovarian tumors
26. p16/MTSI inactivation in ovarian carcinomas: High frequency of reduced protein expression associated with hyper-methylation or mutation in endometrioid and mucinous tumors
27. Differences in p16 gene methylation and expression in benign and malignant ovarian tumors
28. No evidence exists for methylation inactivation of the p16 tumor suppressor gene in ovarian carcinogenesis
29. Rare mutations and no hypermethylation at the CDKN2A locus in epithelial ovarian tumours
30. Increase in the frequency of p16ink4 gene inactivation by hypermethylation in lung cancer during the process of metastasis and its relation to the status of p53
31. Reduced expression of retinoblastoma gene product (pRB) and high expression of p53 are associated with poor prognosis in ovarian cancer
32. Evidence of functional RB protein in epithelial ovarian carcinomas despite loss of heterozygosity at the RB locus
33. Loss of heterozygosity on chromosome 13 is common only in the biologically more aggressive subtypes of ovarian epithetial tumors and is associated with normal retinoblastoma gene expression
34. Abnormal expression of the retinoblastoma gene in ovarian neoplasms and correlation to p53 and K-ras mutations
35. Molecular analysis of the retinoblastoma gene in primary ovarian cancer cells
36. Expression of p16 induces transcriptional downregulation of the RB gene
37. Differential expression and cell cycle regulation of the cyclin-dependent kinase 4 inhibitor p16Ink4
38. Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16
39. Ovarian cancer cells that coexpress endogenous Rb and p16 are insensitive to overexpression of functional p16 protein
40. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest
41. ARF, participates in a regulatory feedback loop with p53 and MDM2
42. Tumor spectrum in ARF-deficient mice
43. Alterations and hypermethylation of the p14(ARF) gene in gastric cancer
44. INK4A/MTS1 gene
45. Chromosomal mapping of members of the cdc2 family of protein kinases, cdk3, cdk6, PISSLRE, and PITALRE, and a cdk inhibitor, p27Kip1, to regions involved in human cancer
46. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27
47. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas
48. Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer
49. Frequent loss of expression of the cyclin-dependent kinase inhibitor p27 in epithelial ovarian cancer